Effect of Pioglitazone on Insulin Resistance and Atherosclerosis in Renal Allograft Recipients Without Diabetes

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

83 participants

Study Classification

INTERVENTIONAL

Study Start Date

2004-11-30

Study Completion Date

2007-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study was to evaluate the effect of pioglitazone treatment on insulin secretion, insulin resistance, and progression of atherosclerosis in renal allograft recipients without preoperative history of diabetes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Does Thiazolidinedione Therapy Improve Endothelial Function and Preserve Renal Function

NCT00586261

Chronic Kidney Disease

TERMINATED NA

Pioglitazone, Body Composition,Insulin Sensitivity and Protein Metabolism in ESRD

NCT01253928

ESRD

UNKNOWN PHASE4

Metabolic and Renal Effects of Rosiglitazone in Kidney Transplant

NCT00309309

Kidney Transplant

COMPLETED PHASE2

Rosiglitazone and Insulin Resistance in Renally Impaired Patients

NCT00452166

Chronic Kidney Disease Insulin Resistance

TERMINATED PHASE3

Effects of Rosiglitazone on Renal Hemodynamics and Proteinuria of Type 2 Diabetic Patients With Renal Insufficiency Due to Overt Diabetic Nephropathy

NCT00324675

Type 2 Diabetes Overt Diabetic Nephropathy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a prospective, randomized, open-label study. The pioglitazone treatment group received 30mg pioglitazone at 2 weeks after renal transplantation for 12 months.

After treatment, we estimated insulin sensitivity index for transplantation,first phase and second phase insulin secretion, secretion area under the curve,and carotid intima-media thickness.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Kidney Transplantation Insulin Resistance Atherosclerosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Group Type EXPERIMENTAL

Pioglitazone

Intervention Type DRUG

The pioglitazone treatment group received 30mg pioglitazone at 2 weeks after renal transplantation for 12 months.

2

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Pioglitazone

The pioglitazone treatment group received 30mg pioglitazone at 2 weeks after renal transplantation for 12 months.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Renal allograft recipients were eligible to participate in the study if they were aged ≥ 18 years, had no previous history of organ transplantation and were not currently using steroids or other immunosuppressants.

Exclusion Criteria

* Diabetes before transplantation
* Severe metabolic or infectious disease
* Hepatic disease
* Congestive heart failure (New York Heart Association II-IV)
* Cadaver donor kidney donor transplantation
* Unstable condition of the transplanted kidney

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No